Aegerion in the News

The following is a selection of news stories and events in which Aegerion is featured.

Xconomy: Two Years After Rising from Ashes, Aegerion Preps for Drug Debut
When Marc Beer joined Cambridge, MA-based Aegerion Pharmaceuticals (NASDAQ:AEGR) as CEO in August 2010, the company was $4 million in debt, nearly insolvent, and “not following a clear path,” he says. By October of that year, Beer, a former Genzyme executive, had worked out a development plan for Aegerion’s cholesterol-lowering drug and taken the company public, raising $48.8 million.